is glp 1 patented Medicines Patent Pool Executive Director Charles Gore tells Devex that one of his priorities in his last year on the job to get a license for GLP-1 therapies. But he admits How the Future of GLP-1

Safety: The most common side effects are mild gastrointestinal symptoms, such as nausea or diarrhea, which typically improve with time

He is not affiliated with the TB-500 / thymosin beta-4 research line

Such advancements in oral formulation technology represent a significant step toward making GLP-1 agonist therapy more accessible and acceptable to patients

D.et al (2022)

High), and individuals without a history of HF (Class IV

If in fact future studies robustly establish a beneficial effect of the drug class in HF, it may allow for broader adoption of GLP-1 RAs in the prevalent CVD, ultimately contributing to addressing the unmet medical need that continues to persist in the prevention or management of, in particular, HFpEF